Imetelstat Expanded Access
Expanded Access Treatment With Imetelstat For Adult Participants With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Are Transfusion-Dependent And Have Failed to Respond or Have Lost Response or Are Ineligible For Erythropoiesis-Stimulating Agents (ESAs)
More Information
- Trial Status
- Completed
- Trial Phase
- Expanded Access
- Sponsors
- Geron Corporation
- Tags
- Telomerase Inhibitor
- Trial Type
- Treatment
- Last Update
- 3 months ago
- SparkCures ID
- 1735
- NCT Identifier
- NCT05937568
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.